<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396418</url>
  </required_header>
  <id_info>
    <org_study_id>STEEER‐AF</org_study_id>
    <nct_id>NCT04396418</nct_id>
  </id_info>
  <brief_title>Stroke Prevention and Rhythm Control Therapy STEEER-AF</brief_title>
  <acronym>STEEER‐AF</acronym>
  <official_title>Stroke Prevention and Rhythm Control Therapy: Evaluation of an Educational Programme of the European Society of Cardiology in a Cluster‐Randomised Trial in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soladis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective trial with hospitals/health centres across 6 different European countries,
      being randomised to either a structured education programme as the intervention or no
      additional education as the control. To determine whether a comprehensive educational
      programme for healthcare professionals will increase the rate of appropriate stroke
      prevention and rhythm control therapy in patients with atrial fibrillation (AF) and adherence
      to Guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, parallel group, two-arm, unblinded, international, cluster-randomized controlled
      trial.

      Intervention arm: A 16-week blended learning programme targeting stroke prevention and rhythm
      control therapy at the healthcare professional level, with controlled assessments, a
      commitment to change plan, and reinforcement actions Control arm: No added education of
      healthcare professionals 70 centres with a cluster size of 25 patients; total estimated
      number of patients 1750.

      8-12 weeks patient recruitment period at each centre; 16 weeks educational intervention
      period; primary &amp; secondary outcomes at 6-9 months post-randomisation; remote follow-up for
      clinical events (no new patient contact) at 18 months from randomisation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to ESC Guidelines in Atrial Filbrillation</measure>
    <time_frame>25 months per centre</time_frame>
    <description>Full adherence to guidelines for stroke prevention rhythm control therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of relevant guidelines adhered to</measure>
    <time_frame>25 months per centre</time_frame>
    <description>Proportion of relevant guidelines adhered to for stroke prevention and rhythm control</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Process outcome</measure>
    <time_frame>25 months per centre</time_frame>
    <description>Improvement in knowledge and guideline-adherent practice by healthcare professionals using the educational intervention</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1750</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 16-week blended learning programme targeting stroke prevention and rhythm control therapy at the healthcare professional level, with controlled assessments, a commitment to change plan, and reinforcement actions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No added education of healthcare professionals</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Education</intervention_name>
    <description>Randomization between two groups at site level. One cluster with education and one without.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with AF

          -  Patient consents to data collection at baseline and follow-up.

        Exclusion Criteria (patients only):

          -  Patients aged under 18 years of age,

          -  Pregnant or planning pregnancy,

          -  Participating in another clinical trial of an investigational medicinal product or
             device,

          -  Life expectancy of less than 2 years.

        Patient assessment: Baseline (time of recruitment) and at follow-up routine appointment
        (6-9 months), plus remote follow-up at 18 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hein Heidbuchel</last_name>
    <role>Study Chair</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dipak Kotecha</last_name>
    <role>Study Director</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle I van Gelder</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Groningen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Boveda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp Sommer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruhr-Universität Bochum, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Boriani</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Modena &amp; Reggio Emilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maciej Sterliński</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Mont</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Rajappan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Céline Arsac</last_name>
    <phone>0033489872075</phone>
    <email>carsac@escardio.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patti-Ann M McNeill</last_name>
    <phone>0033492948637</phone>
    <email>pmcneill@escardio.org</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

